Product Details



OVERACTIVE BLADDER TREATMENT MARKET - GLOBAL FORECAST TO 2023

Overactive Bladder Treatment Market by Pharmacotherapy (Anticholinergic- Solifenacin, Oxybutynin, Fesoterodine, Darifenacin; Mirabegron; BOTOX; Neurostimulation), Disease Type (Idiopathic and Neurogenic Bladder Over activity) and Region - Global Forecast 2023



The Overactive Bladder Treatment market, in terms of value, is projected to grow at a CAGR of XX% from 2017 to 2023. The market is estimated to be USD XX Billion in 2018, and is projected to reach XX Billion by 2023. In this study, 2017 has been considered the base year, and 2018 to 2023 the forecast period, for estimating the market size of the global market.

OBJECTIVES OF THE STUDY

  • To define, describe, and forecast the Overactive Bladder Treatment market segmented on the basis of by Pharmacotherapy (Anticholinergic- Solifenacin, Oxybutynin, Fesoterodine, Darifenacin; Mirabegron; BOTOX; Neurostimulation), Disease Type (Idiopathic and Neurogenic Bladder Over activity) and Region
  • To forecast the market size in terms of value for various segments with respect to four main regions: North America, Europe, APAC, and RoW
  • To provide detailed information regarding the major factors influencing the growth of the Overactive Bladder Treatment market (drivers, restraints, opportunities, and industry-specific challenges)
  • To provide a detailed overview of the value chain in the Overactive Bladder Treatment market and analyze the market trends with Porter’s five forces analysis
  • To analyze the opportunities in the market for various stakeholders by identifying the high-growth segments of the Overactive Bladder Treatment market
  • To strategically profile the key players and comprehensively analyze their market position in terms of ranking and core competencies, along with detailing the competitive landscape for the market leaders
  • To analyze competitive developments such as new product launches and developments; agreements and contracts; mergers and acquisitions; and expansions in the global Overactive Bladder Treatment market

Market Segementation,

Overactive Bladder Treatment Market, by Pharmacotherapy

Anticholinergics

Solifenacin

Oxybutynin

Darifenacin

Fesoterodine

Tolterodine

Trospium

Other Anticholinergics*

Mirabegron

BOTOX

Neurostimulation

Overactive Bladder Treatment Market, by Disease Type

Idiopathic Bladder Overactivity

Neurogenic Bladder Overactivity

Overactive Bladder Treatment Market, by Region

America

Europe

Asia-Pacific

RoW

Table of Contents

1 Introduction

2 Research Methodology

3 Executive Summary 

4 Market Overview
    4.1 Introduction
    4.2 Drivers
    4.3 Restraints
    4.4 Opportunities
    4.5 Challenges

5 Global Overactive Bladder Treatment Market, By Pharmacotherapy
    5.1 Introduction
    5.2 Anticholinergics
           5.2.1 Solifenacin
           5.2.2 Oxybutynin
           5.2.3 Fesoterodine
           5.2.4 Darifenacin
           5.2.5 Tolterodine
           5.2.6 Trospium
           5.2.7 Other Anticholinergics
    5.3 Mirabegron
    5.4 Botox
    5.5 Neurostimulation
    5.6 Intravesical Instillation

6 Global Overactive Bladder Treatment Market, By Disease
    6.1 Introduction
    6.2 Idiopathic Overactive Bladder 
    6.3 Neurogenic Overactive Bladder
           6.3.1 Introduction
           6.3.2 Overactive Bladder in Parkinson's disease
           6.3.3 Overactive Bladder in Stroke
           6.3.4 Overactive Bladder in Multiple Sclerosis
           6.3.5 Overactive Bladder in Spinal Cord Injury
           6.3.6 Overactive Bladder in Other Disorders

7 Global Overactive Bladder Treatment Market, By Region
    7.1 Introduction
    7.2 America

    7.3 Europe
    7.4 Asia-Pacific
    7.5 Rest of the World (RoW)

8 Company Profiles
    (Business Overview, Products & Services, Financials, Key Developments)*
     8.1 Astellas Pharma Inc.
     8.2 Pfizer, Inc. 
     8.3 Teva Pharmaceutical Industries Limited 
     8.4 Allergan, PLC. 
     8.5 Mylan N.V. 
     8.6 Endo International PLC 
     8.7 Hisamitsu Pharmaceutical Co., Inc.
     8.8 Satori
     8.9 Aurobindo Pharma Limited 
     8.10 Johnson & Johnson
     8.11 Intas Pharmaceuticals Ltd. 
     8.12 Apotex Inc. 
     8.13 Macleods Pharmaceuticals Ltd. 
     8.14 Medtronic PLC
     8.15 Cogentix Medical, Inc. 

                             *Details Might Not Be Captured in Case of Unlisted Companies.

Single User   1530.00

Multiple User   2200.00
Latest Product